Compare CNSP & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNSP | PPCB |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | Australia |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 1.9M |
| IPO Year | 2019 | N/A |
| Metric | CNSP | PPCB |
|---|---|---|
| Price | $2.35 | $0.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 31.4K | ★ 6.3M |
| Earning Date | 05-15-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.10 |
| 52 Week High | $10.59 | $10.69 |
| Indicator | CNSP | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | 42.85 |
| Support Level | $2.06 | N/A |
| Resistance Level | $2.95 | $0.13 |
| Average True Range (ATR) | 0.28 | 0.02 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 45.46 | 17.23 |
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.